MX2012015112A - Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. - Google Patents
Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.Info
- Publication number
- MX2012015112A MX2012015112A MX2012015112A MX2012015112A MX2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A MX 2012015112 A MX2012015112 A MX 2012015112A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary hypertension
- receptor antagonists
- adenosine receptor
- treating pulmonary
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36028910P | 2010-06-30 | 2010-06-30 | |
| PCT/US2011/042379 WO2012003220A1 (en) | 2010-06-30 | 2011-06-29 | Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012015112A true MX2012015112A (es) | 2013-05-28 |
Family
ID=44343985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012015112A MX2012015112A (es) | 2010-06-30 | 2011-06-29 | Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120003329A1 (https=) |
| EP (1) | EP2595630A1 (https=) |
| JP (1) | JP2013533882A (https=) |
| KR (1) | KR20130088834A (https=) |
| CN (1) | CN103237548A (https=) |
| AU (1) | AU2011271510A1 (https=) |
| BR (1) | BR112012032766A2 (https=) |
| CA (1) | CA2802891A1 (https=) |
| EA (1) | EA201291274A1 (https=) |
| MX (1) | MX2012015112A (https=) |
| WO (1) | WO2012003220A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| JP2017048116A (ja) * | 2014-01-10 | 2017-03-09 | 国立研究開発法人国立国際医療研究センター | 肺高血圧症治療薬 |
| WO2019157337A1 (en) * | 2018-02-08 | 2019-08-15 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| ES2975753T3 (es) | 2018-03-05 | 2024-07-12 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos |
| WO2022187649A1 (en) * | 2021-03-05 | 2022-09-09 | Tosk, Inc. | Uridine phosphorylase inhibitors to prevent or treat drug-induced pulmonary dysfunction |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DE60206756T2 (de) | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
| UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| DE10303639B4 (de) | 2003-01-30 | 2016-05-25 | Zf Friedrichshafen Ag | Vorrichtung zur Steuerung einer hydraulisch betätigbaren Kupplung eines Automatgetriebes |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| EP1799221A1 (en) | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| EP1891070A1 (en) | 2005-06-16 | 2008-02-27 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| EP2101777B1 (en) * | 2006-12-12 | 2015-05-20 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| EP2268641B1 (en) | 2008-03-26 | 2014-09-03 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
-
2011
- 2011-06-29 BR BR112012032766A patent/BR112012032766A2/pt not_active IP Right Cessation
- 2011-06-29 KR KR1020137001490A patent/KR20130088834A/ko not_active Withdrawn
- 2011-06-29 US US13/172,609 patent/US20120003329A1/en not_active Abandoned
- 2011-06-29 JP JP2013518651A patent/JP2013533882A/ja active Pending
- 2011-06-29 EA EA201291274A patent/EA201291274A1/ru unknown
- 2011-06-29 AU AU2011271510A patent/AU2011271510A1/en not_active Abandoned
- 2011-06-29 CN CN2011800417298A patent/CN103237548A/zh active Pending
- 2011-06-29 MX MX2012015112A patent/MX2012015112A/es not_active Application Discontinuation
- 2011-06-29 WO PCT/US2011/042379 patent/WO2012003220A1/en not_active Ceased
- 2011-06-29 CA CA2802891A patent/CA2802891A1/en not_active Abandoned
- 2011-06-29 EP EP11730524.3A patent/EP2595630A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012003220A1 (en) | 2012-01-05 |
| KR20130088834A (ko) | 2013-08-08 |
| AU2011271510A1 (en) | 2013-01-10 |
| CA2802891A1 (en) | 2012-01-05 |
| EA201291274A1 (ru) | 2013-12-30 |
| EP2595630A1 (en) | 2013-05-29 |
| CN103237548A (zh) | 2013-08-07 |
| US20120003329A1 (en) | 2012-01-05 |
| JP2013533882A (ja) | 2013-08-29 |
| BR112012032766A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| PH12012502512A1 (en) | 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| WO2011121418A9 (en) | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| IN2012DN02177A (https=) | ||
| IN2012DN00754A (https=) | ||
| MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
| MX2014001946A (es) | Inhibidores del canal de potasio medularmente externo renal. | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| NZ608813A (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| WO2012040636A3 (en) | Compounds and methods for treating diseases mediated by protease activated receptors | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| MX2015006720A (es) | D-metadona para el tratamiento de sintomas psiquiatricos. | |
| IN2014DN06964A (https=) | ||
| MX2012015112A (es) | Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. | |
| UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
| MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
| MX342525B (es) | Uso de antagonistas del receptor de adenosina a2b para tratar insuficiencia cardiaca y arritmia en pacientes post-infarto al miocardio. | |
| MX2011008857A (es) | Derivados de oxiindol con actividad agonistica del receptor de motilina. | |
| PH12012502300A1 (en) | Nicotinic receptor non-competitive antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |